m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00575)
Target Name | Circ_ASK1 | ||||
---|---|---|---|---|---|
Gene Name | Circ_ASK1 |
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
Circ_ASK1
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | Increased YTHDF2-mediated endoribonucleolytic cleavage of m6A-modified Circ_ASK1 accounts for its downregulation in gefitinib-resistant cells. Either METTL3 silencing or YTHDF2 silencing suppressed the decay of circASK1 in HCC827-GR cells. This study provides a novel therapeutic target to overcome gefitinib resistance in LUAD patients. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Lung adenocarcinoma | ICD-11: 2C25.0 | ||
Responsed Drug | Gefitinib | Approved | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | SPC-A1 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6955 |
SK-LU-1 | Lung adenocarcinoma | Homo sapiens | CVCL_0629 | |
NCI-H1993 | Lung adenocarcinoma | Homo sapiens | CVCL_1512 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
BEAS-2B | Normal | Homo sapiens | CVCL_0168 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
16HBE14o- | Normal | Homo sapiens | CVCL_0112 | |
In-vivo Model | Established a xenograft model in BALB/c nude mice by inoculating HCC827-GR cells transfected with the constructs for circASK1 silencing, ASK1-272a.a overexpression and ASK1-272a.a overexpression/circASK1 knockdown | |||
YTH domain-containing family protein 2 (YTHDF2) [READER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | Increased YTHDF2-mediated endoribonucleolytic cleavage of m6A-modified Circ_ASK1 accounts for its downregulation in gefitinib-resistant cells. Either METTL3 silencing or YTHDF2 silencing suppressed the decay of circASK1 in HCC827-GR cells. This study provides a novel therapeutic target to overcome gefitinib resistance in LUAD patients. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Lung adenocarcinoma | ICD-11: 2C25.0 | ||
Responsed Drug | Gefitinib | Approved | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | SPC-A1 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6955 |
SK-LU-1 | Lung adenocarcinoma | Homo sapiens | CVCL_0629 | |
NCI-H1993 | Lung adenocarcinoma | Homo sapiens | CVCL_1512 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
BEAS-2B | Normal | Homo sapiens | CVCL_0168 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
16HBE14o- | Normal | Homo sapiens | CVCL_0112 | |
In-vivo Model | Established a xenograft model in BALB/c nude mice by inoculating HCC827-GR cells transfected with the constructs for circASK1 silencing, ASK1-272a.a overexpression and ASK1-272a.a overexpression/circASK1 knockdown | |||
Lung cancer [ICD-11: 2C25]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | Increased YTHDF2-mediated endoribonucleolytic cleavage of m6A-modified Circ_ASK1 accounts for its downregulation in gefitinib-resistant cells. Either METTL3 silencing or YTHDF2 silencing suppressed the decay of circASK1 in HCC827-GR cells. This study provides a novel therapeutic target to overcome gefitinib resistance in LUAD patients. | |||
Responsed Disease | Lung adenocarcinoma [ICD-11: 2C25.0] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Gefitinib | Approved | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | SPC-A1 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6955 |
SK-LU-1 | Lung adenocarcinoma | Homo sapiens | CVCL_0629 | |
NCI-H1993 | Lung adenocarcinoma | Homo sapiens | CVCL_1512 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
BEAS-2B | Normal | Homo sapiens | CVCL_0168 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
16HBE14o- | Normal | Homo sapiens | CVCL_0112 | |
In-vivo Model | Established a xenograft model in BALB/c nude mice by inoculating HCC827-GR cells transfected with the constructs for circASK1 silencing, ASK1-272a.a overexpression and ASK1-272a.a overexpression/circASK1 knockdown | |||
Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | Increased YTHDF2-mediated endoribonucleolytic cleavage of m6A-modified Circ_ASK1 accounts for its downregulation in gefitinib-resistant cells. Either METTL3 silencing or YTHDF2 silencing suppressed the decay of circASK1 in HCC827-GR cells. This study provides a novel therapeutic target to overcome gefitinib resistance in LUAD patients. | |||
Responsed Disease | Lung adenocarcinoma [ICD-11: 2C25.0] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Responsed Drug | Gefitinib | Approved | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | SPC-A1 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6955 |
SK-LU-1 | Lung adenocarcinoma | Homo sapiens | CVCL_0629 | |
NCI-H1993 | Lung adenocarcinoma | Homo sapiens | CVCL_1512 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
BEAS-2B | Normal | Homo sapiens | CVCL_0168 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
16HBE14o- | Normal | Homo sapiens | CVCL_0112 | |
In-vivo Model | Established a xenograft model in BALB/c nude mice by inoculating HCC827-GR cells transfected with the constructs for circASK1 silencing, ASK1-272a.a overexpression and ASK1-272a.a overexpression/circASK1 knockdown | |||
Gefitinib
[Approved]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | Increased YTHDF2-mediated endoribonucleolytic cleavage of m6A-modified Circ_ASK1 accounts for its downregulation in gefitinib-resistant cells. Either METTL3 silencing or YTHDF2 silencing suppressed the decay of circASK1 in HCC827-GR cells. This study provides a novel therapeutic target to overcome gefitinib resistance in LUAD patients. | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Lung adenocarcinoma | ICD-11: 2C25.0 | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | SPC-A1 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6955 |
SK-LU-1 | Lung adenocarcinoma | Homo sapiens | CVCL_0629 | |
NCI-H1993 | Lung adenocarcinoma | Homo sapiens | CVCL_1512 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
BEAS-2B | Normal | Homo sapiens | CVCL_0168 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
16HBE14o- | Normal | Homo sapiens | CVCL_0112 | |
In-vivo Model | Established a xenograft model in BALB/c nude mice by inoculating HCC827-GR cells transfected with the constructs for circASK1 silencing, ASK1-272a.a overexpression and ASK1-272a.a overexpression/circASK1 knockdown | |||
Experiment 2 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | Increased YTHDF2-mediated endoribonucleolytic cleavage of m6A-modified Circ_ASK1 accounts for its downregulation in gefitinib-resistant cells. Either METTL3 silencing or YTHDF2 silencing suppressed the decay of circASK1 in HCC827-GR cells. This study provides a novel therapeutic target to overcome gefitinib resistance in LUAD patients. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Lung adenocarcinoma | ICD-11: 2C25.0 | ||
Cell Process | Cell apoptosis | |||
In-vitro Model | SPC-A1 | Endocervical adenocarcinoma | Homo sapiens | CVCL_6955 |
SK-LU-1 | Lung adenocarcinoma | Homo sapiens | CVCL_0629 | |
NCI-H1993 | Lung adenocarcinoma | Homo sapiens | CVCL_1512 | |
NCI-H1975 | Lung adenocarcinoma | Homo sapiens | CVCL_1511 | |
NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens | CVCL_1483 | |
HEK293T | Normal | Homo sapiens | CVCL_0063 | |
HCC827 | Lung adenocarcinoma | Homo sapiens | CVCL_2063 | |
BEAS-2B | Normal | Homo sapiens | CVCL_0168 | |
A-549 | Lung adenocarcinoma | Homo sapiens | CVCL_0023 | |
16HBE14o- | Normal | Homo sapiens | CVCL_0112 | |
In-vivo Model | Established a xenograft model in BALB/c nude mice by inoculating HCC827-GR cells transfected with the constructs for circASK1 silencing, ASK1-272a.a overexpression and ASK1-272a.a overexpression/circASK1 knockdown | |||